Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study

March 27, 2026 updated by: Mayo Clinic
To collect and analyze specimens that will correlate with clinical outcomes such as acute and late toxicities, quality of life, local control, and survival of patients treated with photon/proton therapy.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

15000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Recruiting
        • Mayo Clinic
        • Contact:
          • Clinical Trials Referral Office
          • Phone Number: 855-776-0015
        • Principal Investigator:
          • Nadia N. Laack, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

All patients being treated at Mayo Clinic with photon/ proton therapy.

Description

Inclusion Criteria:

  1. Treated with photon/proton at Mayo Clinic Rochester in Radiation Oncology
  2. Radiation therapy for curative intent

Exclusion Criteria:

None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
analyze acute and late toxicities using CTCAE 4.03
Time Frame: Patients will be followed for the duration of their life, an expected average of 20 years
Patients will be followed for the duration of their life, an expected average of 20 years
analyze quality of life using LASA-3 and FACT-E
Time Frame: Patients will be followed for the duration of their life, an expected average of 20 years
Patients will be followed for the duration of their life, an expected average of 20 years

Secondary Outcome Measures

Outcome Measure
Time Frame
analyze local control through tumor assessments
Time Frame: Patients will be followed for the duration of their life, an expected average of 20 years
Patients will be followed for the duration of their life, an expected average of 20 years
analyze survival by contacting patient and EMR (electronic medical record) review
Time Frame: Patients will be followed for the duration of their life, an expected average of 20 years
Patients will be followed for the duration of their life, an expected average of 20 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mayo Clinic

Investigators

  • Principal Investigator: Nadia N. Laack, MD, Mayo Clinic

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 23, 2015

Primary Completion (Estimated)

April 30, 2031

Study Completion (Estimated)

April 30, 2031

Study Registration Dates

First Submitted

May 11, 2015

First Submitted That Met QC Criteria

May 27, 2015

First Posted (Estimated)

May 29, 2015

Study Record Updates

Last Update Posted (Actual)

April 1, 2026

Last Update Submitted That Met QC Criteria

March 27, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 15-000136

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Solid Tumors

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe